Janssen Cilag is one of the world’s leading research-based pharmaceutical companies, and the prostate cancer drug that they manufacture, Abirateron has been shown to extend the lives of late-stage prostate cancer sufferers by more than three months.
The National Institute for Health and Clinical Excellence (NICE) have revised their recommendations and prostate cancer drug is now approved for used by the National Health Service. Janssen will be providing the prostate cancer drug to the NHS at a discounted price.
Developed by the Institute of Cancer Research, the prostate cancer drug took two decades to develop, as Professor Alan Ashworth explains, “This drug was discovered at the Institute of Cancer Research and is the result of more than two decades of dedicated work by our scientists and collaborators.
“In clinical trials of men with advanced prostate cancer who have already tried chemotherapy, it has been shown to extend life by an average of four months and improve quality of life.”